Small and mid-sized biotech companies face unique challenges when bringing novel therapies to market. While many large pharmaceutical companies have the knowledge and in-house talent to clear regulatory hurdles and conduct efficient clinical trials, smaller companies often do not. That’s why small and mid-sized biotechs need to THINK BIG when working to deliver life-changing therapies to patients with unmet needs.
Join seasoned experts as they share successful strategies they’ve used to help small and mid-sized companies get innovative treatments to the people who need them. Each episode in our three-part series is packed with insights and practical tips for success.
Check out the podcast episodes below.⬆
- Ep. 3 Operationalizing Cell and Gene Therapy Trials
- Ep. 2 Why Multinational Clinical Trials Are Key to Bringing Novel Therapies to Market
- Ep. 1 Defining the Regulatory Roadmap for Product Success
Operationalizing Cell and Gene Therapy Trials
In the third and final episode, Desmond Cabrera, global lead for cell and gene therapy at Allucent, shares how small- and mid-sized companies can operationalize cell and gene therapy trials.